Heres how we can help you take charge of your weight and your health
"Head-to-head trials are a gold standard for comparing potential treatments," Kenneth Custer, executive vice president and president of Lilly Cardiometabolic Health, said in a news release
They demonstrated that pre-treatment with the GLP-1 receptor antagonist, exendin-(939), significantly reduced the entry of both GLP-1 and exendin-4 into various brain regions
a peptide approved for clinical use) and GLP-1 (purple), respectively
It is studied for its potent effects on weight loss, metabolic regulation, and insulin sensitivity
Free expedited shipping with tracking in email and the patient portal